Literature DB >> 9438510

Breast stereotactic core biopsy washings: abundant cell samples from clinically occult lesions for flow cytometric DNA analysis.

P C Stomper1, R M Budnick, C C Stewart.   

Abstract

RATIONALE AND
OBJECTIVES: The object of this study was to determine by flow cytometry the cellular and DNA content of the washings of core biopsy samples and needles obtained during stereotactic core biopsies of clinically occult suspicious lesions.
METHODS: Fourteen-gauge core multipass biopsy inner-needle saline washings obtained after dislodgment of the tissue core samples (n = 30) and 14-ga mammotomy core biopsy specimen washings (n = 30) were analyzed by flow cytometry.
RESULTS: Multipass core biopsy needle washings of 7 malignant and 23 benign lesions yielded a median of 10,584 cells per lesion (range 562-29,019 cells). Mammotomy core biopsy specimen washings of 10 malignant and 20 benign lesions yielded a median of 12,164 cells per lesion (range 1,295-115,150). Forty-four (73%) washings in each technique had more than 5000 cells. Flow cytometric DNA ploidy analysis was possible in 60 (100%) and the S phase percentage determination was possible in 59 (98%) of the washings. Aneuploidy was detected in 53% of malignant lesions and 2% of benign lesions.
CONCLUSIONS: Core biopsy specimen or needle washings provide abundant fresh cellular material from clinically occult lesions for DNA analysis by flow cytometry.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9438510     DOI: 10.1097/00004424-199801000-00008

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Molecular sentinel-on-chip for SERS-based biosensing.

Authors:  Hsin-Neng Wang; Anuj Dhawan; Yan Du; Dale Batchelor; Donovan N Leonard; Veena Misra; Tuan Vo-Dinh
Journal:  Phys Chem Chem Phys       Date:  2013-03-15       Impact factor: 3.676

2.  Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles.

Authors:  R Bermudo; D Abia; A Mozos; E García-Cruz; A Alcaraz; A R Ortiz; T M Thomson; P L Fernández
Journal:  Br J Cancer       Date:  2011-10-18       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.